Study of Pregnancy And Neonatal Health (SPAN)
A legfontosabb adatok
- Ki végzi
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Hol
- Birmingham, Chapel Hill, Durham, Falls Church, Murray, New Orleans, Philadelphia és Salt Lake City (Egyesült Államok)Mind a 8 helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Résztvevők
- 304 fő vett részt
- Kezdés
- 2023. jan. 20.
- Befejezés
- 2024. dec. 16.
- A vizsgálat típusa
- Beavatkozással járó, 7 csoport
- A vizsgált kezelések
- Childbirth
- A regiszteradat frissítve
- 2025. december 24.
- Miért állt le
- Low enrollment
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Csak nők
- Egészséges önkéntesek
- Részt vehetnek
A regiszter feltételei, szó szerint
Mind a 19 feltétel megnézéseKevesebb
Ki vehet részt
- Aim 3 (GDM randomized trial, TIME) inclusion criteria:
- Women inclusion criteria:
- Age ≥ 18 Years
- Verified diagnosis of Gestational Diabetes Mellitus (GDM) with abnormal glucose levels*** or meeting other criteria for poor control, specifically any one of the following: Estimated fetal weight ≥90th percentile (LGA), Polyhydramnios, and or Demonstrate noncompliance or nonadherence as defined clinically, including missing visits, not keeping accurate log, etc; ***One or more elevated fasting blood glucoses OR three or more elevated post-prandial blood glucoses after receiving education about appropriate diet and lifestyle modification (e.g. physical activity)
- Accurate gestational age as verified by ultrasound
- Singleton gestation
- English or Spanish speaker
- Plans to deliver at the study site hospital
- Ability to provide informed consent to be randomized to initiation of delivery
Ki nem vehet részt
- Previous stillbirth defined as fetal demise ≥ 20 weeks of gestation
- Pregnancies with concurrent conditions and other indications for earlier delivery will also be excluded
- Self-reported history of alcohol dependency disorder and/or other drug/substance dependency in the past year
- Known infectious diseases associated with neonatal morbidity (e.g. malaria, cytomegalovirus, rubella, toxoplasmosis, syphilis or Zika virus)
- Genetic disorders, aneuploidy and known major fetal anomalies
- Pre-gestational diabetes*; *will be defined as diabetes diagnosis before pregnancy OR before 13 weeks of gestation with a documented fasting plasma glucose ≥ 126 mg/dL, random plasma glucose ≥ 200 mg/dL, 2 hour post glucose ≥ 200 mg/dL during an oral glucose tolerance test (75 g glucose load), or hemoglobin A1c ≥ 6.5%.110
- Aim 3 (GDM randomized trial, TIME) exclusion criteria:
- Teratogen exposure (e.g. cyclophosphamide, valproic acid, warfarin)
- Fetal demise
- Participation in another interventional study that influences management of labor and delivery or perinatal morbidity or mortality
Helyszínek itt: Egyesült Államok
- University of Alabama at BirminghamBirmingham, Egyesült Államok
- University of North Carolina, Chapel HillChapel Hill, Egyesült Államok
- Duke University Perinatal Research CenterDurham, Egyesült Államok
- Inova Fairfax HospitalFalls Church, Egyesült Államok
- Intermountain HealthcareMurray, Egyesült Államok
- Ochsner BaptistNew Orleans, Egyesült Államok
- University of PennsylvaniaPhiladelphia, Egyesült Államok
- University of UtahSalt Lake City, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study will conduct a randomized trial among women with gestational diabetes (GDM). Study of Pregnancy And Neonatal health (SPAN), TIMing of dElivery (TIME) is a randomized trial that will recruit up to 3,450 pregnant women with uncontrolled GDM and randomize the timing of their delivery. Women with GDM who are approached for the trial and are found eligible but do not consent to participating in randomization for delivery will be asked to consent for chart review only (estimated additional n=3,000). The primary objective is to determine the best time to initiate delivery for GDM-complicated deliveries (defined as the time when risk of illness and death for the newborn is the lowest) between 37-39 weeks.
A vizsgálat 7 csoportja
- Intervention Arm 1A vizsgált kezelés
Intervention Arm 1 Experimental Initiation of Delivery by induction or planned cesarean at 37 weeks 0-2 days.
Kezelés: Childbirth
- Intervention Arm 2A vizsgált kezelés
Intervention Arm 2 Experimental Initiation of Delivery by induction or planned cesarean at 37 weeks 3-5 days.
Kezelés: Childbirth
- Intervention Arm 3A vizsgált kezelés
Initiation of Delivery by induction or planned cesarean at 37 weeks 6 days to 38 weeks and 1 day.
Kezelés: Childbirth
- Intervention Arm 4A vizsgált kezelés
Intervention Arm 4 Experimental Initiation of Delivery by induction or planned cesarean at 38 weeks 2-4 days.
Kezelés: Childbirth
- Intervention Arm 5A vizsgált kezelés
Initiation of Delivery by induction or planned cesarean at 38 weeks 5 days to 39 weeks and 0 days.
Kezelés: Childbirth
- Intervention Arm 6A vizsgált kezelés
Intervention Arm 6 Experimental Initiation of Delivery by induction or planned cesarean at 39 weeks 1-3 days.
Kezelés: Childbirth
- Intervention Arm 7A vizsgált kezelés
Intervention Arm 7 Experimental Initiation of Delivery by induction or planned cesarean at 39 weeks 4-6 days.
Kezelés: Childbirth
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Study of Pregnancy And Neonatal Health (SPAN): TIMing of dElivery (TIME) Trial
- A regiszteradat frissítve
- 2025. december 24.